We recently published a list of Dividend Stock Portfolio For Income: Top 10 Stocks to Buy. In this article, we are going to ...

Shares of Bristol Myers Squibb Co. BMY slid 1.43% to $57.38 Wednesday, on what proved to be an all-around mixed trading ...

Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions.

The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...

Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...

In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the novel antibody-drug conjugate was ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Rajiv Onat, India head, digital technology and engineering, Regeneron, acknowledged Telangana’s role in creating a ...

The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI ...

I always find myself rooting not necessarily for the actor who gave the best performance — because, really, who can say which ...

Allogene Therapeutics is developing allogeneic CAR-T cells for cancer and autoimmune diseases. Read why I'm bullish on ALLO ...

Many investors get this one wrong. Even though they are going to be net buyers of stocks for many years to come, they are ...